Asset
VONOPRAZAN FUMARATE
PHATHOM PHARMACEUTICALS INC. COMMON STOCK
Revenue
| Product | Latest period | Revenue |
|---|---|---|
| VOQUEZNA | Q1 2026 | $58.3M |
Each figure is the latest quarter this company reported for that product, a fourth quarter being the year less nine months when no filing states one. A figure belongs to the product it was reported for, so nothing here is summed and a substance in several products shows once per product.
Clinical trials (0)
No records yet.
FDA applications (4)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| NDA 215151 | 2023-11-01 | NDA | PHATHOM PHARMACEUTICALS INC |
| NDA 215152 | 2022-05-03 | NDA | PHATHOM PHARMACEUTICALS INC |
| NDA 215153 | 2022-05-03 | NDA | PHATHOM PHARMACEUTICALS INC |
| NDA 218710 | — | NDA | PHATHOM PHARMACEUTICALS INC |
Marketed products (6)
- VOQUEZNA
- VOQUEZNA
- VOQUEZNA
- VOQUEZNA
- VOQUEZNA DUAL PAK
- VOQUEZNA TRIPLE PAK